La Reina schreef op 7 december 2020 12:47:
In de Lancet (toonaangevend medium):Commente730
www.thelancet.com/rheumatology Vol 2 December 2020
Other clinical trials are underway investigating other inhibitors of the terminal complement pathway against COVID-19, including C3 inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5 inhib-itors—eculizumab (NCT04346797 and NCT04355494), ravulizumab (NCT04369469 and NCT04390464), and zilucoplan (NCT04382755); and a C5a receptor inhibitor—avdoralimab (NCT04371367). Furthermore,
C1 esterase inhibitors, which block the classical complement pathway, are under investigation—conestat alfa (NCT04414631) and ruconest (NCT04530136).Beyond the fundamental question of whether anti-complement therapy improves outcomes in COVID-19, the ongoing clinical trials hopefully will address both critical and nuanced questions in the campaign against COVID-19 over the ensuing months.
www.thelancet.com/pdfs/journals/lanrh...